Specimen Collection Manual and Test Catalog
TYPE AND SCREEN
Geisinger Epic Procedure Code: LAB3207 Geisinger Epic ID: 15475Whole Blood
6 mL whole blood or 3 full EDTA microcollection tubes.
Add-on testing is not permitted. Specimen must be labeled with patient's first and last name, medical record number or some unique other identifier (e.g.,billing number, NOT date of birth). Date of collection and phlebotomist identification (full name or tech ID) must be available.
- If Rover is used to ensure proper patient identification, a second collection is not required. A second sample is not required if the patient has a historical type in any Geisinger facility. A second type will be performed on the same sample. The properly labeled specimen will be sent to the Blood Bank.
- If Rover is not used for patient identification (i.e., nurse line draws), 2 samples from separate collections are required if the patient has no previous testing at Geisinger. The properly labeled specimen will be sent to the Blood Bank in a separate biohazard bag.
Do not centrifuge or aliquot.
Preferred specimen: Room temperature (less than 24 hours). If greater than 24 hours, specimen must be stored and transported at 2-8° C.
Specimen must be less than 3 days old for testing.
Tube containing gel separator. Incomplete label ID (see collection notes).
Antibody-positive specimens will be worked up to the extent necessary to identify the antibody. Geisinger Health System workflow is to order type and screen followed by a prepare and transfuse order in Epic if blood products are needed.
The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only.
ANTIBODY SCREEN (ABSC) and BLOOD GROUP & TYPE (ABO/RH)
TSC, TYPE, SCREEN, CROSSMATCH
Type and screen battery must be performed to provide compatible blood. "Type" includes ABO and Rh typing of the patient's red blood cells. "Screen" includes a red blood cell antibody screen, which can detect common clinically significant antibodies to red blood cells. For prenatal patients, the patient's Rh determines if she is a Rhogam candidate, and the antibody screen determines if the mother has any pre-existing IgG alloantibodies that could cross the placenta.